1. Home
  2. SACH vs NXTC Comparison

SACH vs NXTC Comparison

Compare SACH & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$0.96

Market Cap

48.6M

Sector

Real Estate

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$11.61

Market Cap

44.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SACH
NXTC
Founded
2010
2015
Country
United States
United States
Employees
29
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.6M
44.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SACH
NXTC
Price
$0.96
$11.61
Analyst Decision
Hold
Strong Buy
Analyst Count
3
3
Target Price
$2.00
$23.00
AVG Volume (30 Days)
161.8K
25.8K
Earning Date
03-12-2026
03-05-2026
Dividend Yield
20.72%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,378,000.00
Revenue This Year
$150.14
N/A
Revenue Next Year
$4.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.23
52 Week High
$1.35
$15.74

Technical Indicators

Market Signals
Indicator
SACH
NXTC
Relative Strength Index (RSI) 34.89 45.47
Support Level N/A $10.73
Resistance Level $1.12 $13.47
Average True Range (ATR) 0.04 1.12
MACD -0.01 -0.10
Stochastic Oscillator 22.31 38.89

Price Performance

Historical Comparison
SACH
NXTC

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: